# Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment

> **NCT04647526** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company** · enrollment: 455 (actual)

## Conditions studied

- Metastatic Castration-Resistant Prostate Cancer

## Interventions

- **DRUG:** [Lu-177]-PNT2002
- **DRUG:** Abiraterone
- **DRUG:** Enzalutamide

## Key facts

- **NCT ID:** NCT04647526
- **Lead sponsor:** POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-02-25
- **Primary completion:** 2023-11-01
- **Final completion:** 2028-03
- **Target enrollment:** 455 (ACTUAL)
- **Last updated:** 2026-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04647526

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04647526, "Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04647526. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*